The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals.

Autor: Berner AM; Barts Cancer Institute, Queen Mary University of London, United Kingdom; Gender Identity Clinic London, Tavistock and Portman NHS Trust, United Kingdom. Electronic address: alison.berner@nhs.net., Atkinson SE; St Bartholomew's Hospital, Barts Health NHS Trust, United Kingdom.
Jazyk: angličtina
Zdroj: Best practice & research. Clinical endocrinology & metabolism [Best Pract Res Clin Endocrinol Metab] 2024 Sep; Vol. 38 (5), pp. 101909. Date of Electronic Publication: 2024 Jun 26.
DOI: 10.1016/j.beem.2024.101909
Abstrakt: There is evidence that gender-affirming hormone treatment (GAHT) for transgender individuals modulates their risk for specific malignancies including breast and prostate cancer, and meningiomas. However, there is insufficient data to make precise risk estimates accounting for age and inherited cancer risk. As such, screening recommendations remain broad. Even less evidence exists for best practice in the management of active or historical cancers in the transgender population. Guidance is therefore mainly extrapolated from cisgender populations but with considerations of the significant benefits of GAHT in the face of any hormonal risk. Clinical experience, the multidisciplinary team and shared decision making with the patient are vital in providing person-centred care, while further research is acquired.
Competing Interests: Declaration of Competing Interest AMB has received honoraria for non-promotional education on cancer care in transgender patients from Pfizer, Lilly and Astellas, and a fellowship grant to employ staff for the UK Cancer and Transition Service from Gilead. SA declares no conflicts of interest.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: